Articles

A.N.A.L.Y.T.I.C.S corner - A Necessary Approach: Leveraging Your Targe…

23rd April 2014

A.N.A.L.Y.T.I.C.S corner - A Necessary Approach: Leveraging Your Target’s Insights Creatively & StrategicallyAdrian Smith

Adrian Smith of Havas Life Metro shares his thoughts on how to interpret and integrate successful mobile campaigns in pharmaceutical marketing.Build it and they will come –interpreting & integrating mobile... Read more

Understanding the natural history of disease – a fundamental strategy …

23rd April 2014

Understanding the natural history of disease – a fundamental strategy during drug development and beyondAnnette Stemhagen

How important is it to understand the natural history of disease before embarking on drug development? Annette Stemhagen of United BioSource Corporation discusses.Having an in-depth understanding of the disease or... Read more

The technological tipping point for pharma sales and marketing

22nd April 2014

The technological tipping point for pharma sales and marketingKabir Shahani & Barry Crowther

In the wake of the eyeforpharma Barcelona event, IMS Health's Kabir Shahani and Barry Crowther present the case for technology being not just an enabler for new pharma engagement with... Read more

Digital pharma update: loves me, loves me not?

22nd April 2014

Digital pharma update: loves me, loves me not?Denise Silber

In her latest article, Denise Silber, founder of Doctors 2.0 & You conference, a pharmaphorum partner, explores the world of digital pharma and how this area has advanced since she... Read more

News

Roche’s Kadcyla ‘unaffordable’ for NHS

23rd April 2014

Roche’s Kadcyla ‘unaffordable’ for NHSAndrew McConaghie

Roche's new breast cancer treatment Kadcyla has been rejected by NICE in draft guidance, with the cost effectiveness watchdog criticising the high price set by the company.NICE says Kadcyla costs... Read more

Sarepta and FDA agree plan for Muscular Dystrophy drug

22nd April 2014

Sarepta and FDA agree plan for Muscular Dystrophy drugAndrew McConaghie

Sarepta has overcome a major regulatory obstacle and now plans to file its Duchenne Muscular Dystrophy treatment with the FDA by the end of 2014. The US company had received a... Read more

Novartis and GSK’s multi-billion dollar swaps to transform both compan…

22nd April 2014

Novartis and GSK’s multi-billion dollar swaps to transform both companiesAndrew McConaghie

Novartis has unveiled a dazzling multi-billion dollar business deal which sees it divest its vaccines and animal health divisions, build its oncology portfolio, and create a new joint venture market... Read more

NHS England approves early funding for Sovaldi

17th April 2014

NHS England approves early funding for Sovaldi  Andrew McConaghie

NHS England is to spend £18.7 million to make new Hepatitis C treatment Sovaldi available to patients with the most advanced disease.Around 500 patients who have acute liver failure, and/or... Read more

Audio & Video

Rare Disease Day tweetchat

 

To view a full transcript of the discussion from this #hcsmeu tweetchat held on 28th February 2014 please click View more

Is there common ground for engagement be…

Doctors net webinar

 

The growth of online networks for doctors has been accompanied by recognition from the pharmaceutical industry that these digital meeting grounds can be... View more

Executive Perspectives: Jane Griffiths

 

In the latest in our series of interviews with senior executives who are steering the global pharma industry through a period of unparalleled change, pharmaphorum... View more

Full round table: Oncology shaping the …

 

Watch the full round table video debate on 'oncology shaping the... View more

White Papers

Who are the pharma social media butterfl…

Who are the pharma social media butterflies?Joanne Wunder, Caroline Howe, Andrea Visone and Laura Clewes

Social media has got everyone talking and it seems like everyone in pharma is talking about social media, so Ogilvy Healthworld figured it was time to analyse who were the... View info

Engage with confidence: Managing online …

Engage with confidence: Managing online adverse event reportingSiva Nadarajah

The pharmaceutical industry is waking up to the enormous potential offered by social media and other online data sources for informing better decisions around drug development and commercialization. Here, Siva... View info

Digital excellence in the global pharmac…

Digital excellence in the global pharmaceutical industry in 2014Tim van Tongeren and Dennis van Rooij

As pharmaceutical companies all look to step up their digital capabilities, this survey of digital leaders from across big pharma, exclusively first published on pharmaphorum, reveals an interesting picture of... View info

Patient research – the changing landscap…

Patient research – the changing landscape: Harnessing the voice of the citizen expertBrian Mondry and Jo Boxall

Empowered patients, or citizen experts as they are often called, are becoming one of the most powerful forces in healthcare, which means the pharmaceutical industry must learn to effectively engage... View info

Further News & Articles

Pharma Gets Social: Pinterest for Pharma, revisited

Daniel Ghinn provides an update on pharma's use of Pinterest since he last wrote about it two years ago. He updat... Read more

Articles

Tunnah’s musings: Social media in the pharma boardroom

Attending the Boehringer Ingelheim annual press conference, Paul Tunnah took the opportunity to catch up with its he... Read more

Articles

US approval for Glaxo’s Tanzeum

GlaxoSmithKline has gained FDA approval for its new diabetes treatment Tanzeum.

The drug ... Read more

News

When measuring European regulatory approval, the timestamp matters

Daniel Sanchez and Yin Ho explore the concept of cycle time in regulatory decisions in the pharma industry and their... Read more

Articles

Boehringer pursues aggressive new products strategy

Boehringer Ingelheim announces flat growth for 2013 and anticipates a tough 2014, but pins future growth on a... Read more

News

Sovaldi ‘cost effective but not affordable’ for NHS

A leading charity says new Hepatitis C drug Sovaldi is a huge step forward in treating the disease – but says... Read more

News